Twist Bioscience Valuation Multiples

Twist Bioscience Overview

About Twist Bioscience

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company’s proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Founded

2013

HQ

Employees

979

Website

twistbioscience.com

Sectors

Diagnostics & GenomicsBioTechDeepTech

Financials (LTM)

Revenue: $411M

EBITDA: ($36M)

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

Twist Bioscience Financials

Twist Bioscience reported last 12-month revenue of $411M and negative EBITDA of ($36M).

In the same LTM period, Twist Bioscience generated $213M in gross profit, ($36M) in EBITDA losses, and had net loss of ($91M).

Twist Bioscience P&L

In the most recent fiscal year, Twist Bioscience reported revenue of $377M and EBITDA of ($47M).

Twist Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX

Twist Bioscience Stock Performance

Twist Bioscience has current market cap of $4B, and enterprise value of $4B.

Twist Bioscience's stock price is $59.81.

Twist Bioscience Valuation Multiples

Twist Bioscience trades at 8.7x EV/Revenue multiple, and (99.1x) EV/EBITDA.

Twist Bioscience Financial Valuation Multiples

As of April 20, 2026, Twist Bioscience has market cap of $4B and EV of $4B.

Equity research analysts estimate Twist Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Twist Bioscience has a P/E ratio of (40.1x).

Twist Bioscience Margins & Growth Rates

Twist Bioscience's revenue in the last 12 month grew by 16%.

Twist Bioscience's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.

Twist Bioscience's rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Twist Bioscience's rule of X is 36% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Twist Bioscience Public Comps

See public comps and valuation multiples for other Diagnostics & Genomics comps.

Twist Bioscience M&A Activity

Twist Bioscience acquired XXX companies to date.

Last acquisition by Twist Bioscience was on XXXXXXXX, XXXXX. Twist Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Twist Bioscience Investment Activity

Twist Bioscience invested in XXX companies to date.

Twist Bioscience made its latest investment on XXXXXXXX, XXXXX. Twist Bioscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).